News

   

Combination of Poolbeg and HOOKIPA Pharma Inc.

The boards of directors (each a "Board") of HOOKIPA Pharma Inc.…

European Energy and Novo Holdings announce joint venture to triple renewable energy capacity of German onshore wind parks

A partnership between Novo Holdings and European Energy will…

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis

alfapump® is the first US approved active implantable medical…

TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic in acute ischemic stroke (AIS) and TTP

TGD001 is being developed to offer patients with clotting…

Ottimo Pharma Raises over $140 Million in Series A Financing

Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital,…

Novo Holdings and SUBRA join forces to accelerate development of innovative superconductor technology for power transmission and fusion energy

Today, Novo Holdings and SUBRA announce a partnership to fast-track…

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark

A new comprehensive initiative at the Technical University of…

Denmark’s new AI supercomputer Gefion ranked as 7th fastest storage systems in the world

Denmark's state-of-the-art AI supercomputer, Gefion, has achieved…

NeoPhore appoints Michael Shih as Chief Executive Officer

Highly experienced corporate development leader with a track…

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

Licensing agreement gives Elevation Oncology access to Synaffix's…

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

New therapies will allow patients greater choice and flexibility…

General Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological search

Enable Medicine is at the forefront of using generative AI…

SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease

SB-007 is the only IND-cleared, clinical-stage therapeutic…

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

Statistically significant difference in arrested disease in leriglitazone…

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity…

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225

NorthStar will supply non-carrier added Actinium-225, a radionuclide,…

Industry leading survey of Venture Capital (VC) life sciences investors of funds managing c.$300bn

VCs favouring new investments over existing portfolio and have…

Noema Pharma extends Series B financing round, closing at CHF130 Million ($147 Million)

EQT Life Sciences expands the Series B with additional capital,…

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics…

Poolbeg Pharma plc presents POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

All doses of POLB 001 significantly reduced clinically observed…

We’d love to hear from you.

For more information about Optimum Strategic Communications, please get in touch.

Get in touch
© Optimum Strategic Communications.